- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02395653
Safety and Clinical Utility Study of SSEC Fentanyl 40 mcg for Acute Post-op Pain Management in Pediatric Participants
25. september 2017 opdateret af: The Medicines Company
An Open Label Evaluation of the Safety and Clinical Utility of the Active, Separated System With Enhanced Controller (SSEC) Fentanyl 40 mcg for the Management of Acute Postoperative Pain in Pediatric Patients 12 to Less Than 18 Years of Age
The objective of this study is to evaluate the safety and clinical utility of the active, SSEC fentanyl 40 micrograms (mcg) for the management of acute, postoperative pain in pediatric participants.
Studieoversigt
Detaljeret beskrivelse
An open label evaluation of the safety and clinical utility of the active, SSEC fentanyl 40 mcg for the management of acute postoperative pain in pediatric participants 12 to less than 18 years of age.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
71
Fase
- Fase 3
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
California
-
Palo Alto, California, Forenede Stater, 94304
- Packard Children's Hospital at Stanford
-
-
Florida
-
Miami, Florida, Forenede Stater, 33136
- University of Miami/Jackson Memorial Hospital
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30342
- Children's Healthcare of Atlanta
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21287
- Johns Hopkins Hospital, Charlotte R. Bloomberg Children's Center
-
-
Missouri
-
Saint Louis, Missouri, Forenede Stater, 63110
- St. Louis Children's Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- The Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, Forenede Stater, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75235
- Children's Medical Center of Dallas
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98104
- Harborview Medical Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Children's Hospital of Wisconsin
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
12 år til 17 år (Barn)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Participants whose parent(s) or guardian(s) have/has signed and dated an informed consent form for the participant to participate in the study, or participants who have provided written assent to participate in the study
- Male or female inpatients, age 12 to <18 years of age inclusive on the day of surgery
- Participants capable of understanding and cooperating with the requirements of the study, including being able to report their pain intensity using the 11-point Numeric Rating Scale and operate the SSEC
- American Society of Anesthesiologists physical status I, II or III
- Body weight of at least 40.0 kilogram (kg)
- Postoperative participants who have undergone general or regional anesthesia for abdominal, pelvic/genitourinary, orthopedic, or thoracic surgery
- Postoperative participants who have been observed during recovery and are expected to remain hospitalized and have pain requiring parenteral opioids (that is, intravenous [IV] patient-controlled anesthesia) for the next 24 hours or longer
- Participants who are awake and breathing spontaneously with a respiratory rate of 14 to 18 breaths per minute, peripheral capillary oxygen saturation ≥93% (with or without supplemental oxygen), and able to answer questions and follow commands
- Participants who have been observed during recovery, who are awake, able to answer questions and follow commands, and who have been comfortable for at least 30 minutes, with a pain intensity score ≤4 (numeric rating scale 0-10), with or without titration to comfort with IV opioids
Exclusion Criteria:
- Participants who have undergone any surgery on the airway, head, or neck
- Participants who received an extended-release opioid within 48 hours prior to Hour 0 or who are expected to have postoperative analgesia supplied by a continuous regional technique or participant-controlled epidural analgesia
- Participants with a history of allergy or hypersensitivity to fentanyl, skin adhesives, and/or cetylpyridinium chloride
- Participants who are expected to require intensive care or will likely require additional surgical procedures within 36 hours
- Participants who received intra-operative and/or postoperative administration of opioids other than morphine, hydromorphone, fentanyl, sufentanil, or alfentanil. Exception: If there are no medical contraindications, meperidine (pethidine) up to 0.5 milligram/kg IV is permitted during recovery for shivering
- Participants who require airway support (nasal or oropharyngeal airway intubation, or laryngeal mask airway at the time of final baseline assessments (that is, at the time of IONSYS application [Hour 0])
- Participants who are known or suspected to be opioid tolerant, have a history of opioid dependence within 3 months before the start of the study, or who are known to have used illicit drugs or alcohol within 14 days of the start of the study
- Participants with active generalized skin disorders or active local skin disease that precludes SSEC application to the chest or upper arm
- Participants with any coexisting major medical conditions that are likely to interfere with study procedures including, but not limited to, psychiatric conditions, chronic depression, suicidal ideation, autism
- Positive pregnancy test for any female
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: SSEC Fentanyl
SSEC fentanyl iontophoretic transdermal system, 40 mcg fentanyl per activation.
|
An opioid that has been administered parenterally as an anesthetic and analgesic for more than 20 years.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Assessment Of Participant's Ability To Use The SSEC
Tidsramme: Completed at the time of the participant's termination of study treatment (up to 72 hours after study drug administration)
|
Investigator's assessment of participant's ability to use the SSEC system safely and effectively.
The assessment consisted of a 4-level categorical evaluation (poor, fair, good, and excellent).
Because of the descriptive nature of this study, no formal statistical hypothesis testing was performed.
|
Completed at the time of the participant's termination of study treatment (up to 72 hours after study drug administration)
|
Assessment Of Adherence Of The SSEC System To Skin
Tidsramme: Immediately prior to removal at each 24-hour time point, or at early withdrawal, for up to 3 consecutive days (up to 72 hours)
|
The adhesion of each SSEC was evaluated immediately prior to removal at each 24-hour time point, or at early withdrawal.
Adhesion was recorded using the following classification: System adhered to at least 90% of the application area with no edges unattached; System adhered between 75% and 89%; System was <75% adhered and not taped; System was secured with tape.
The number of SSEC systems for all time points in each category is presented.
Because of the descriptive nature of this study, no formal statistical hypothesis testing was performed.
|
Immediately prior to removal at each 24-hour time point, or at early withdrawal, for up to 3 consecutive days (up to 72 hours)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Change From Baseline To 1 Hour And 24 Hours In Skin Irritation Score After SSEC Removal
Tidsramme: Baseline, 1 hour and 24 hours after SSEC removal.
|
Skin irritation at the SSEC application site was to be assessed immediately prior to placement of the study system and at 1 and 24 hours after removal of each study system.
The application site was to be scored using the following scale: 0=No evidence of irritation; 1=Minimal erythema, barely perceptible; 2=Definite erythema, readily visible, minimal edema, or minimal papular response; 3=Erythema and papules; 4=Definite edema; 5=Erythema, edema, and papules; 6=Vesicular eruption; 7=Strong reaction spreading beyond the application site.
|
Baseline, 1 hour and 24 hours after SSEC removal.
|
Number Of Participants To Experience Clinically Relevant Respiratory Depression (CRRD)
Tidsramme: From the time of application of the first system through 7 days following end of study drug administration.
|
Respiratory function and occurrence of CRRD was defined as simultaneous occurrence of bradypnoea (respiratory rate <10 breaths per minute for participants 9-15 years of age and sustained for 1 minute, or <8 breaths per minute for participants 16-17 years of age), with excessive sedation (that is, the participant is not easily aroused).
|
From the time of application of the first system through 7 days following end of study drug administration.
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Elliot J Krane, MD, Stanford Children's Health
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Generelle publikationer
- Hartrick CT, Bourne MH, Gargiulo K, Damaraju CV, Vallow S, Hewitt DJ. Fentanyl iontophoretic transdermal system for acute-pain management after orthopedic surgery: a comparative study with morphine intravenous patient-controlled analgesia. Reg Anesth Pain Med. 2006 Nov-Dec;31(6):546-54. doi: 10.1016/j.rapm.2006.08.011.
- Chelly JE, Grass J, Houseman TW, Minkowitz H, Pue A. The safety and efficacy of a fentanyl patient-controlled transdermal system for acute postoperative analgesia: a multicenter, placebo-controlled trial. Anesth Analg. 2004 Feb;98(2):427-433. doi: 10.1213/01.ANE.0000093314.13848.7E.
- Grond S, Hall J, Spacek A, Hoppenbrouwers M, Richarz U, Bonnet F. Iontophoretic transdermal system using fentanyl compared with patient-controlled intravenous analgesia using morphine for postoperative pain management. Br J Anaesth. 2007 Jun;98(6):806-15. doi: 10.1093/bja/aem102. Erratum In: Br J Anaesth. 2008 Jan;100(1):146.
- Minkowitz HS, Rathmell JP, Vallow S, Gargiulo K, Damaraju CV, Hewitt DJ. Efficacy and safety of the fentanyl iontophoretic transdermal system (ITS) and intravenous patient-controlled analgesia (IV PCA) with morphine for pain management following abdominal or pelvic surgery. Pain Med. 2007 Nov-Dec;8(8):657-68. doi: 10.1111/j.1526-4637.2006.00257.x.
- Minkowitz HS, Yarmush J, Donnell MT, Tonner PH, Damaraju CV, Skowronski RJ. Safety and tolerability of fentanyl iontophoretic transdermal system: findings from a pooled data analysis of four clinical trials. J Opioid Manag. 2010 May-Jun;6(3):203-10. doi: 10.5055/jom.2010.0018.
- Viscusi ER, Reynolds L, Chung F, Atkinson LE, Khanna S. Patient-controlled transdermal fentanyl hydrochloride vs intravenous morphine pump for postoperative pain: a randomized controlled trial. JAMA. 2004 Mar 17;291(11):1333-41. doi: 10.1001/jama.291.11.1333.
- Viscusi ER, Reynolds L, Tait S, Melson T, Atkinson LE. An iontophoretic fentanyl patient-activated analgesic delivery system for postoperative pain: a double-blind, placebo-controlled trial. Anesth Analg. 2006 Jan;102(1):188-94. doi: 10.1213/01.ane.0000183649.58483.77.
- Viscusi ER, Siccardi M, Damaraju CV, Hewitt DJ, Kershaw P. The safety and efficacy of fentanyl iontophoretic transdermal system compared with morphine intravenous patient-controlled analgesia for postoperative pain management: an analysis of pooled data from three randomized, active-controlled clinical studies. Anesth Analg. 2007 Nov;105(5):1428-36, table of contents. doi: 10.1213/01.ane.0000281913.28623.fd.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
29. juni 2015
Primær færdiggørelse (Faktiske)
12. september 2016
Studieafslutning (Faktiske)
12. september 2016
Datoer for studieregistrering
Først indsendt
10. marts 2015
Først indsendt, der opfyldte QC-kriterier
20. marts 2015
Først opslået (Skøn)
23. marts 2015
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
26. oktober 2017
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
25. september 2017
Sidst verificeret
1. september 2017
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Postoperative komplikationer
- Smerte
- Neurologiske manifestationer
- Smerter, postoperativ
- Lægemidlers fysiologiske virkninger
- Depressive midler til centralnervesystemet
- Agenter fra det perifere nervesystem
- Analgetika
- Sensoriske systemagenter
- Bedøvelsesmidler, intravenøst
- Bedøvelsesmidler, general
- Bedøvelsesmidler
- Analgetika, Opioid
- Narkotika
- Adjuvanser, anæstesi
- Fentanyl
Andre undersøgelses-id-numre
- PD2013-002
- 2014-002405-37 (EudraCT nummer)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ja
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Smerter, postoperativ
-
Wake Forest University Health SciencesRekruttering
-
University of California, San DiegoJohns Hopkins University; United States Department of Defense; The Cleveland... og andre samarbejdspartnereTilmelding efter invitationKirurgisk amputation af nedre ekstremiteter | Post-amputation Phantom Limb PainForenede Stater
-
Brugmann University HospitalTrukket tilbagePhantom Limb Pain (PLP) | Primær/sekundær arhyperalgesiBelgien
-
Quiropraxia y EquilibrioUniversidad Nacional Andres BelloAfsluttetMyofascial Trigger Point Pain (MTrP)Chile
-
East Carolina UniversityTrukket tilbage
-
Quiropraxia y EquilibrioIkke rekrutterer endnuMyofascial Trigger Point Pain (MTrP)Chile
-
Rijnstate HospitalSaluda Medical Pty LtdTilmelding efter invitationPolyneuropatier | Kronisk smertesyndrom | Multi Focal Pain | Mislykket nakkekirurgi syndromHolland
-
Oslo University HospitalUniversity of Oslo; Fysiofondet; Oslo Metropolitan UniversityRekrutteringGluteal tendinopati | Trochanterisk bursitis | Lateral hoftesmerter | GTPS - Greater Trochanteric Pain SyndromeNorge
-
University of KentuckyDonJoy OrthopedicsAfsluttetPostoperativ Quadriceps Svaghed | Postoperativ Quadriceps-hæmning | Overholdelse af postoperativ behandling | Postoperativ underekstremitetsfunktionForenede Stater
-
Ospedale Misericordia e DolceUkendtPostoperativ smerte | Thyroidektomi | Postoperativ kvalme og opkast | Postoperativ stemmefunktionItalien
Kliniske forsøg med fentanyl
-
University of Maryland, BaltimoreFood and Drug Administration (FDA)AfsluttetPeer Review, ForskningForenede Stater
-
Alexza Pharmaceuticals, Inc.Afsluttet
-
Ente Ospedaliero Cantonale, BellinzonaIkke rekrutterer endnu
-
University of Texas Southwestern Medical CenterAfsluttetGraviditetForenede Stater
-
Janssen Research & Development, LLCAfsluttet
-
University of PatrasUkendtDødfødt kejsersnitGrækenland
-
Johns Hopkins UniversityAfsluttet
-
University of Maryland, BaltimoreFood and Drug Administration (FDA)Afsluttet
-
AstraZenecaAfsluttetKronisk obstruktiv lungesygdom (KOL)Tyskland